Paper Details

  1. Home
  2. Paper Details

FDA Approval Summary: TAS-102.

Author: AgarwalRajiv, CaoXianhua, EnglundErika, HeKun, HelmsWhitney S, KeeganPatricia, KhasarSachia, LemerySteven J, MarcusLeigh, PazdurRichard, StephensOlen, WangYaning, WearneEmily, YuJingyu, YuanWeishi, ZhaoHong

Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This article summarizes the results of a clinical trial evaluating the efficacy and safety of TAS-102 for treating metastatic colorectal cancer. TAS-102 demonstrated a statistically significant improvement in overall survival and progression-free survival compared to placebo. The most common side effects were anemia, neutropenia, and fatigue.
Paper Details　
Original Abstract of the Article :
The FDA approved TAS-102 (Lonsurf; Taiho Oncology, Inc.) for the treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy; an anti-VEGF biological therapy; and if RAS wild type, an anti-EGF...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1158/1078-0432.CCR-16-2157

データ提供：米国国立医学図書館（NLM）

TAS-102: A New Oasis in the Desert of Metastatic Colorectal Cancer

Metastatic colorectal cancer (mCRC) is a challenging disease, like a relentless sandstorm in the desert. This study evaluated the effectiveness of TAS-102, a new drug, in treating patients with mCRC who had already received other treatments. TAS-102 was compared to a placebo in a large, randomized trial. The results showed that patients receiving TAS-102 lived significantly longer and experienced a delay in tumor progression compared to those receiving the placebo. This is like discovering a new oasis in the desert, providing a lifeline for those who are struggling to survive.

Survival and Progression-Free Survival: Navigating the Desert of Cancer

The study found that TAS-102 significantly improved overall survival, extending the median survival time by 7.1 months in the TAS-102 group compared to 5.3 months in the placebo group. This is a significant finding, like discovering a hidden well in the desert that provides water for a much longer time. The drug also significantly prolonged progression-free survival, giving patients more time before their cancer progressed. This is like finding a sturdy camel that can carry you further and longer through the desert.

Camel's Advice: Staying Hydrated in the Desert of Cancer

While TAS-102 shows promise in treating mCRC, it's important to remember that it's not a cure. It's like finding a temporary oasis in the desert, providing relief and support, but the journey is still long and challenging. This study highlights the importance of ongoing research and development of new treatments for cancer, like searching for new oases to sustain life in the desert.

Dr. Camel's Conclusion

This study demonstrates the potential of TAS-102 as a valuable new treatment option for patients with metastatic colorectal cancer. The drug's ability to prolong survival and delay disease progression offers a beacon of hope in the fight against this challenging disease. It's like finding a new path through the desert, leading to a more promising future for those facing the harsh realities of cancer.

Date :
  1. Date Completed 2018-03-21
  2. Date Revised 2022-03-21
Further Info :

Pubmed ID

28213365

DOI: Digital Object Identifier

10.1158/1078-0432.CCR-16-2157

Related Literature

Article Analysis
・Side Effects of trifluridine and tipiracil
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.